Katie Kelley

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6602
San Francisco CA 94158
Phone415-353-9888
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard College, Boston, MAA.B.05/1997Biochemical Sciences
    University of California Los Angeles, Los Angeles, CAM.D.05/2002School of Medicine
    University of California Los Angeles, Los Angeles, CAResidency05/2005Internal Medicine
    University of California Los Angeles, Los Angeles, CAChief Residency06/2006Internal Medicine
    University of California San Francisco, San Francisco, CAFellowship10/2009Hematology/Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

    Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas. Gastroenterology. 2024 Jun 10. Hsu BY, Driscoll J, Human Cholangiocarcinogenesis Project, Tateno C, Mattis AN, Kelley RK, Willenbring H. PMID: 38866344.
      View in: PubMed   Mentions:    Fields:    
    2. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024 Jun 04; 1-8. Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. PMID: 38861293.
      View in: PubMed   Mentions:    Fields:    
    3. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024 Jun 03; 65(6):938-943. Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. PMID: 38697672; PMCID: PMC11149593.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun; 8:e2300494. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. PMID: 38865673.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2024 May 28; JCO2301462. Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. PMID: 38805668.
      View in: PubMed   Mentions:    Fields:    
    6. Evidence and Choice: The BCLC Vision for Tailoring Clinical Decision-Making. J Hepatol. 2024 May 08. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. PMID: 38729354.
      View in: PubMed   Mentions:    Fields:    
    7. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 Jul 01; 80(1):87-101. Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. PMID: 38381705; PMCID: PMC11191046.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Apr; 9(4):310-322. Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. PMID: 38364832.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    9. Author Correction: Hepatocellular carcinoma. Nat Rev Dis Primers. 2024 Feb 12; 10(1):10. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. PMID: 38346997.
      View in: PubMed   Mentions:    Fields:    
    10. Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2024 Feb; 20(2):119-122. Kelley RK. PMID: 38414909; PMCID: PMC10895911.
      View in: PubMed   Mentions:
    11. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2023 Oct 01; 9(10):1423-1431. Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F. PMID: 37615958; PMCID: PMC10450588.
      View in: PubMed   Mentions: 3     Fields:    
    12. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Future Oncol. 2023 Dec; 19(38):2505-2516. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. PMID: 37671641.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma. Clin Pharmacol Ther. 2023 10; 114(4):874-882. Song X, Kelley RK, Green M, Standifer N, Lim K, Zhou D, Dunyak J, Negro A, Kurland JF, Ren S, Khan AA, Gibbs M, Abou-Alfa GK. PMID: 37422678.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    14. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023 07 06; 115(7):870-880. Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. PMID: 37040087; PMCID: PMC10323903.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. Cell Rep Med. 2023 06 20; 4(6):101052. Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudhari S, Kriga Y, Ylaya K, Warner AC, Edmondson EF, Forgues M, Greten TF, Wang XW. PMID: 37224815; PMCID: PMC10313915.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Polyunsaturated Fatty Acid-Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism. Cancer Res. 2023 05 02; 83(9):1543-1557. Munson PV, Adamik J, Hartmann FJ, Favaro PMB, Ho D, Bendall SC, Combes AJ, Krummel MF, Zhang K, Kelley RK, Butterfield LH. PMID: 36847613; PMCID: PMC10152238.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    17. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 06 03; 401(10391):1853-1865. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A, KEYNOTE-966 Investigators. PMID: 37075781.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    18. Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clin Cancer Res. 2023 02 16; 29(4):754-763. Song X, Kelley RK, Khan AA, Standifer N, Zhou D, Lim K, Krishna R, Liu L, Wang K, McCoon P, Negro A, He P, Gibbs M, Kurland JF, Abou-Alfa GK. PMID: 36477555; PMCID: PMC9932581.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    19. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023 06; 20(6):349-365. Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. PMID: 36697706.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    20. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023 01 19; 388(3):228-239. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. PMID: 36652354.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    21. Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer. 2023 Sep; 12(4):372-391. Vogel A, Kelley RK, Johnson P, Merle P, Yau T, Kudo M, Meyer T, Rimassa L. PMID: 37817754; PMCID: PMC10561324.
      View in: PubMed   Mentions:
    22. The evolving role of combination systemic therapies in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2022 Dec; 20(12):709-713. Kelley RK. PMID: 36469664.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature. BMJ Open. 2022 10 26; 12(10):e064954. McNamara MG, Bridgewater J, Goyal L, Jacobs T, Wagner AD, Goldstein D, Shroff R, Moehler M, Lowery M, Bekaii-Saab T, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox J, Valle J. PMID: 36288834; PMCID: PMC9615988.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. The Evolving Role of Combination Systemic Therapies in Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2022 Oct; 18(10):594-598. Kelley RK. PMID: 36397929; PMCID: PMC9666801.
      View in: PubMed   Mentions:
    25. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell Rep. 2022 09 20; 40(12):111384. Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L. PMID: 36130508; PMCID: PMC10060099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    26. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clin Cancer Res. 2022 08 15; 28(16):3537-3545. Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, Pan H, Dillon P, Mhatre SK, Gaillard VE, Hernandez S, Kelley RK, Sangro B. PMID: 35435967.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    27. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 08; 23(8):995-1008. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. PMID: 35798016.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    28. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022 Aug; 1(8):EVIDoa2100070. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. PMID: 38319892.
      View in: PubMed   Mentions: 71     Fields:    
    29. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022 04; 3(4):386-401. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. PMID: 35484418; PMCID: PMC9060366.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    30. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer. 2022 06; 168:91-98. Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK. PMID: 35487183.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    31. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer. 2022 Apr 09; 22(1):377. El-Khoueiry AB, Meyer T, Cheng AL, Rimassa L, Sen S, Milwee S, Kelley RK, Abou-Alfa GK. PMID: 35397508; PMCID: PMC8994237.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    32. Biliary cancer brain metastases: a multi-institution case series with case reports. J Gastrointest Oncol. 2022 Apr; 13(2):822-832. Falkson SR, Zhang K, Bhambhvani HP, Wild JL, Griffin A, Kelley RK, Gephart MH. PMID: 35557587; PMCID: PMC9086048.
      View in: PubMed   Mentions: 1  
    33. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. J Mol Diagn. 2022 04; 24(4):351-364. Silverman IM, Li M, Murugesan K, Krook MA, Javle MM, Kelley RK, Borad MJ, Roychowdhury S, Meng W, Yilmazel B, Milbury C, Shewale S, Feliz L, Burn TC, Albacker LA. PMID: 35176488.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. Am J Clin Oncol. 2022 01 01; 45(1):22-27. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. PMID: 34864778.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022 01 06; 185(1):184-203.e19. Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. PMID: 34963056; PMCID: PMC8862608.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    36. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 01; 23(1):77-90. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. PMID: 34914889.
      View in: PubMed   Mentions: 356     Fields:    Translation:HumansCTClinical Trials
    37. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer. 2022 Jan; 11(1):38-47. Rimassa L, Kelley RK, Meyer T, Ryoo BY, Merle P, Park JW, Blanc JF, Lim HY, Tran A, Chan YW, McAdam P, Wang E, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. PMID: 35222506; PMCID: PMC8820164.
      View in: PubMed   Mentions: 22  
    38. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 03; 76(3):681-693. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. PMID: 34801630; PMCID: PMC8866082.
      View in: PubMed   Mentions: 960     Fields:    Translation:Humans
    39. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer. 2022 03; 126(4):569-575. Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. PMID: 34621044; PMCID: PMC8854685.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    40. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022 02; 12(2):402-415. Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. PMID: 34551969; PMCID: PMC9762334.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    41. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer. 2021 Nov; 10(6):561-571. Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, Behr SC, Onodera C, Zhang K, Bocobo AG, Benson AB, Venook AP, Gordan JD. PMID: 34950179; PMCID: PMC8647100.
      View in: PubMed   Mentions: 7  
    42. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021 09; 9(9). Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. PMID: 34518290; PMCID: PMC8438858.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    43. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. PMID: 34358484.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    44. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021 09 20; 39(27):2991-3001. Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. PMID: 34292792; PMCID: PMC8445563.
      View in: PubMed   Mentions: 161     Fields:    Translation:HumansCTClinical Trials
    45. Hepatocellular Carcinoma - Origins and Outcomes. N Engl J Med. 2021 07 15; 385(3):280-282. Kelley RK, Greten TF. PMID: 34260842.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    46. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021 Jul; 98:102221. El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. PMID: 34029957.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    47. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med. 2021 05; 10(9):3059-3067. Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK. PMID: 33811482; PMCID: PMC8085979.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    48. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 01 21; 7(1):6. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. PMID: 33479224.
      View in: PubMed   Mentions: 1932     Fields:    Translation:Humans
    49. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020 08; 5(4). Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. PMID: 32847838; PMCID: PMC7451459.
      View in: PubMed   Mentions: 37  Translation:Humans
    50. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020 09 15; 26(18):4795-4804. Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. PMID: 32636319; PMCID: PMC7779341.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    51. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020 12; 25(12):e1825-e1836. Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. PMID: 32548867; PMCID: PMC8186405.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    52. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 2020 Jul; 16(21):1525-1536. Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L. PMID: 32491932.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    53. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Adv Ther. 2020 06; 37(6):2678-2695. Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK. PMID: 32424805; PMCID: PMC7467441.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    54. Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer. N Engl J Med. 2020 05 14; 382(20):1953-1955. Kelley RK. PMID: 32402168.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    55. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. PMID: 32416072; PMCID: PMC7523268.
      View in: PubMed   Mentions: 335     Fields:    Translation:HumansCTClinical Trials
    56. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 10 15; 147(8):2190-2198. Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. PMID: 32359091.
      View in: PubMed   Mentions: 171     Fields:    Translation:Humans
    57. Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clin Liver Dis (Hoboken). 2020 Feb; 15(2):53-58. Huppert LA, Gordan JD, Kelley RK. PMID: 32226615; PMCID: PMC7098670.
      View in: PubMed   Mentions: 16  
    58. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS One. 2020; 15(3):e0222259. Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S. PMID: 32210440; PMCID: PMC7094874.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    59. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 05; 23(5):551-558. Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. PMID: 32389219; PMCID: PMC7217867.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    60. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020 02; 72(2):353-363. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. PMID: 31954497.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    61. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020 04; 17(4):238-251. Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. PMID: 31900465; PMCID: PMC7401304.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    62. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. PMID: 30058032; PMCID: PMC6650370.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 01; 5(11):1582-1588. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. PMID: 31486832; PMCID: PMC6735405.
      View in: PubMed   Mentions: 65     Fields:    
    64. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019 10 18; 7(1):267. Keenan BP, Fong L, Kelley RK. PMID: 31627733; PMCID: PMC6798343.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansAnimals
    65. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019 Dec 15; 125(24):4426-4434. Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK. PMID: 31454426; PMCID: PMC8172082.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    66. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019 Aug; 10(4):751-765. Boscoe AN, Rolland C, Kelley RK. PMID: 31392056; PMCID: PMC6657309.
      View in: PubMed   Mentions: 65  
    67. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. PMID: 31363003; PMCID: PMC9292132.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    68. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019 08; 39(8):1468-1477. Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G. PMID: 30963691.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    69. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer. 2019 09 15; 125(18):3234-3241. Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. PMID: 31154669.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    70. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079. Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. PMID: 31109923; PMCID: PMC6677584.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCells
    71. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019 06; 248(2):164-178. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, Bowman S, Talevich E, Ferrell LD, Kakar S, Krings G. PMID: 30690729.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    72. Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma. Clin Nucl Med. 2019 Mar; 44(3):e133-e135. Perez PM, Flavell RR, Kelley RK, Umetsu S, Behr SC. PMID: 30624275.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    73. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. Oncologist. 2019 06; 24(6):747-e218. El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK. PMID: 30598500; PMCID: PMC6656521.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    74. Emerging Role for Systemic Therapy in Earlier Stages of HCC. Int J Radiat Oncol Biol Phys. 2018 12 01; 102(5):1407. Kelley RK. PMID: 31014785.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    75. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. PMID: 35135097.
      View in: PubMed   Mentions: 61     Fields:    
    76. Cabozantinib in Hepatocellular Carcinoma. N Engl J Med. 2018 10 04; 379(14):1384-1385. Abou-Alfa GK, Borgman-Hagey AE, Kelley RK. PMID: 30281991.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    77. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 05; 379(1):54-63. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. PMID: 29972759; PMCID: PMC7523244.
      View in: PubMed   Mentions: 984     Fields:    Translation:HumansCTClinical Trials
    78. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist. 2018 09; 23(9):998-1003. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK. PMID: 29622700; PMCID: PMC6192605.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    79. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. PMID: 29182496; PMCID: PMC6075847.
      View in: PubMed   Mentions: 274     Fields:    Translation:HumansCTClinical Trials
    80. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 02; 15(2):95-111. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. PMID: 28994423; PMCID: PMC5819599.
      View in: PubMed   Mentions: 624     Fields:    Translation:Humans
    81. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    82. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. PMID: 28340509.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    83. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. PMID: 28487467; PMCID: PMC5507643.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    84. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 05; 15(5):563-573. Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. PMID: 28476736; PMCID: PMC5557008.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    85. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017 03 01; 28(3):528-534. Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E. PMID: 28426123; PMCID: PMC5391701.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    86. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. PMID: 28188191; PMCID: PMC5508568.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    87. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. PMID: 28893116; PMCID: PMC5598799.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    88. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110; PMCID: PMC5177572.
      View in: PubMed   Mentions: 10  
    89. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. PMID: 28078106; PMCID: PMC5177567.
      View in: PubMed   Mentions: 9  
    90. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. PMID: 27622582.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansCells
    91. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 05; 23(5):411-8. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. PMID: 27080472; PMCID: PMC4963225.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    92. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    93. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15; 22(6):1348-55. Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL. PMID: 26490310.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    94. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol. 2015 Oct; 16(13):1279-81. Kelley RK. PMID: 26433814; PMCID: PMC4811670.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    95. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290; PMCID: PMC4703532.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCellsCTClinical Trials
    96. A 46-Year-Old Asian Woman With Liver Mass. Semin Oncol. 2015 Oct; 42(5):e67-76. Morris GJ, Covey AM, D'Angelica M, Chang DT, Yen Y, Kelley RK, Greenberg H, Tsioulias G. PMID: 26433558.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Biliary Tract Cancers: Finding Better Ways to Lump and Split. J Clin Oncol. 2015 Aug 20; 33(24):2588-90. Kelley RK, Bardeesy N. PMID: 26195717.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    98. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. PMID: 26177599; PMCID: PMC4832308.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    99. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333; PMCID: PMC4592417.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    100. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer. 2015 Jun; 46(2):161-5. Parks AL, McWhirter RM, Evason K, Kelley RK. PMID: 25662892; PMCID: PMC5321609.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    101. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. PMID: 25884197; PMCID: PMC4399150.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsCTClinical Trials
    102. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar; 13(3):311-8. Trosman JR, Weldon CB, Kelley RK, Phillips KA. PMID: 25736008; PMCID: PMC4372087.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    103. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer Res. 2014 Dec; 34(12):7357-60. Cinar P, Calkins SM, Venook AP, Kelley RK. PMID: 25503172.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    104. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75. Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. PMID: 25242168; PMCID: PMC4323738.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    105. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1152-82. Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. PMID: 25099447.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    106. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. PMID: 25006153; PMCID: PMC4113721.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    107. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    108. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013 Dec; 2(4):33. Subramaniam S, Kelley RK, Venook AP. PMID: 25841912.
      View in: PubMed   Mentions: 50     Fields:    
    109. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191; PMCID: PMC3790192.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    110. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J Clin Oncol. 2013 Oct 01; 31(28):3483-6. Kelley RK. PMID: 23980088.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    111. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-1907. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998; PMCID: PMC3690907.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    112. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013 Jan; 6(1):3-9. Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Torbenson MS, Ferrell L, Pawlik TM, Fong Y, O'Reilly EM, Ma J, McGuire J, Vallarapu GP, Griffin A, Stipa F, Capanu M, Dematteo RP, Venook AP, Abou-Alfa GK. PMID: 23505572; PMCID: PMC3597938.
      View in: PubMed   Mentions: 57  
    113. Novel therapeutics in hepatocellular carcinoma: how can we make progress? Am Soc Clin Oncol Educ Book. 2013. Kelley RK, Venook AP. PMID: 23714481.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    114. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    115. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl. 2012 May; 18(5):509-13. Kelley RK, Hirose R, Venook AP. PMID: 22389236.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    116. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9. Kelley RK, Atreya C, Venook AP, Febbo PG. PMID: 22393192.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    117. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):354-62. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. PMID: 22083023.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    118. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011 Nov; 9 Suppl 5:S1-32; quiz S33. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. PMID: 22138009.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    119. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw. 2011 Nov; 9(11):1293-302. Kelley RK, Wang G, Venook AP. PMID: 22056657; PMCID: PMC3696980.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    120. Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy? J Hepatol. 2012 Jan; 56(1):14-6. Kelley RK, Yao F. PMID: 21872558.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    121. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011 Jun; 10(2):73-80. Kelley RK, Venook AP. PMID: 21859557; PMCID: PMC3561586.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    122. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. PMID: 21245436.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. PMID: 21233242; PMCID: PMC3695822.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    124. KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. PLoS Curr. 2010 Sep 02; 2. Wang G, Kelley RK. PMID: 20877448; PMCID: PMC2940138.
      View in: PubMed   Mentions: 4  
    125. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010 Aug 05; 363(6):596-8. Kelley RK, Venook AP. PMID: 20818898.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    126. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    127. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. 2009 May; 11(3):175-85. Kelley R, Venook AP. PMID: 19336009.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    128. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008 Dec 20; 26(36):5845-8. Kelley RK, Venook AP. PMID: 19029408.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    129. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95. Kelley RK, Ko AH. PMID: 19707431; PMCID: PMC2727779.
      View in: PubMed   Mentions: 37  
    Katie's Networks
    Concepts (341)
    Derived automatically from this person's publications.
    _
    Co-Authors (100)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _